LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-245-0399
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees23
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable
LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions
What is LogicBio Therapeutics' stock symbol?
LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."
How were LogicBio Therapeutics' earnings last quarter?
LogicBio Therapeutics Inc (NASDAQ:LOGC) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.02. View LogicBio Therapeutics' Earnings History.
When is LogicBio Therapeutics' next earnings date?
What price target have analysts set for LOGC?
3 brokers have issued 12 month price objectives for LogicBio Therapeutics' shares. Their forecasts range from $20.00 to $26.00. On average, they anticipate LogicBio Therapeutics' stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 151.1% from the stock's current price. View Analyst Price Targets for LogicBio Therapeutics.
What is the consensus analysts' recommendation for LogicBio Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LogicBio Therapeutics.
What are Wall Street analysts saying about LogicBio Therapeutics stock?
Here are some recent quotes from research analysts about LogicBio Therapeutics stock:
- 1. According to Zacks Investment Research, "LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company's technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. " (11/14/2019)
- 2. Chardan Capital analysts commented, "We see limited read-across on nuclease-free editing controversy On 21 July, researchers from the California posted a manuscript to the bioRxiv preprint server outlining outlining unsuccessful efforts to reproduce efficient nuclease-free genome editing with clade F AAV vectors, based on a 2018 publication from Homology Medicines (unrated), which reported >50% editing with similar AAV vectors isolated from hematopoietic stem cells (AAVHSCs). Increasing attention drawn to the preprint to us may have sent Homology’s share price down >20% by the market close on July 25th. Below, we highlight some considerations for interpreting the data and the extent of potential read-across for other companies in the space." (7/29/2019)
Has LogicBio Therapeutics been receiving favorable news coverage?
News stories about LOGC stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. LogicBio Therapeutics earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for LogicBio Therapeutics.
Are investors shorting LogicBio Therapeutics?
LogicBio Therapeutics saw a drop in short interest during the month of February. As of February 14th, there was short interest totalling 214,300 shares, a drop of 6.5% from the January 30th total of 229,300 shares. Based on an average trading volume of 82,000 shares, the short-interest ratio is currently 2.6 days. Currently, 1.6% of the shares of the company are short sold. View LogicBio Therapeutics' Current Options Chain.
Who are some of LogicBio Therapeutics' key competitors?
Some companies that are related to LogicBio Therapeutics include AVITA MED LTD/S (RCEL), Avrobio (AVRO), Cellectis (CLLS), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Rubius Therapeutics (RUBY), Proteon Therapeutics (PRTO), MeiraGTx (MGTX), Aptose Biosciences (APTO), Replimune Group (REPL), Atara Biotherapeutics (ATRA), GENFIT S A/ADR (GNFT), Prevail Therapeutics (PRVL), Nantkwest (NK) and Compugen (CGEN).
What other stocks do shareholders of LogicBio Therapeutics own?
Who are LogicBio Therapeutics' key executives?
LogicBio Therapeutics' management team includes the folowing people:
- Mr. Frederic Chereau, Pres, CEO & Director (Age 52)
- Mr. Matthias B. Jaffé, Chief Financial Officer (Age 50)
- Mr. Tom Wilton, Chief Bus. Officer (Age 45)
- Dr. Leszek Lisowski Ph.D., Co-Founder
- Dr. Adi Barzel, Co-Founder
When did LogicBio Therapeutics IPO?
(LOGC) raised $77 million in an initial public offering (IPO) on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.
Who are LogicBio Therapeutics' major shareholders?
LogicBio Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Samlyn Capital LLC (3.23%), Board of Trustees of The Leland Stanford Junior University (3.21%), State Street Corp (0.56%), Geode Capital Management LLC (0.41%), Fiduciary Trust Co. (0.14%) and Goldman Sachs Group Inc. (0.11%). View Institutional Ownership Trends for LogicBio Therapeutics.
Which institutional investors are selling LogicBio Therapeutics stock?
Which institutional investors are buying LogicBio Therapeutics stock?
LOGC stock was bought by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Fiduciary Trust Co., Oxford Asset Management LLP, State Street Corp, Barclays PLC, UBS Group AG, Geode Capital Management LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for LogicBio Therapeutics.
How do I buy shares of LogicBio Therapeutics?
Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is LogicBio Therapeutics' stock price today?
One share of LOGC stock can currently be purchased for approximately $9.16.
How big of a company is LogicBio Therapeutics?
LogicBio Therapeutics has a market capitalization of $209.98 million. The company earns $-17,620,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. LogicBio Therapeutics employs 23 workers across the globe.View Additional Information About LogicBio Therapeutics.
What is LogicBio Therapeutics' official website?
How can I contact LogicBio Therapeutics?
LogicBio Therapeutics' mailing address is 99 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-245-0399 or via email at [email protected]
MarketBeat Community Rating for LogicBio Therapeutics (NASDAQ LOGC)
MarketBeat's community ratings are surveys of what our community members think about LogicBio Therapeutics and other stocks. Vote "Outperform" if you believe LOGC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LOGC will underperform the S&P 500 over the long term. You may vote once every thirty days.
